# reload+after+2024-01-20 10:45:27.473856
address1§149 Fifth Avenue
address2§Suite 500
city§New York
state§NY
zip§10010
country§United States
phone§212 994 8250
website§https://minktherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
fullTimeEmployees§37
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Garo H. Armen Ph.D.', 'age': 70, 'title': 'Executive Chairman', 'yearBorn': 1953, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jennifer S. Buell Ph.D.', 'age': 48, 'title': 'President, CEO & Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 812780, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marcus Antonius van Dijk Ph.D.', 'age': 61, 'title': 'Chief Scientific Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 369924, 'exercisedValue': 0, 'unexercisedValue': 325608}, {'maxAge': 1, 'name': 'Ms. Christine M. Klaskin', 'age': 57, 'title': 'Treasurer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 27244, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Heather  Boussios', 'title': 'General Counsel & Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Joy  Zhou Ph.D.', 'title': 'Vice President & Head of CMC', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.047
currency§USD
dateShortInterest§1702598400
forwardEps§-0.63
exchange§NCM
quoteType§EQUITY
shortName§MiNK Therapeutics, Inc.
longName§MiNK Therapeutics, Inc.
firstTradeDateEpochUtc§1634304600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8e937e64-1037-36f6-8809-414881fb7391
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§7.0
targetMeanPrice§8.33
targetMedianPrice§8.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§0.616
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
